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 Introduction to Essential Tremor as a Clinical Entity 
 Essential tremor (ET) is a chronic, progressive, degen-
erative brain disease whose most recognizable feature is 
a 4- to 12-Hz kinetic tremor (that is, tremor occurring 
during volitional movement) of the arms  [1] . The tremor 
may range in severity from mild and functionally unim-
portant to severe and disabling  [2–6] . Aside from arm 
tremor, head and voice tremors may occur as well  [1, 7] . 
The clinical features can include a number of other types 
of tremor, other motor manifestations and nonmotor fea-
tures. In terms of other types of tremor, many patients 
also have intention tremor (that is, tremor while ap-
proaching a target) and rest tremor occurs in some as well 
 [8–10] . Other motor manifestations have been docu-
mented repeatedly. Thus, changes in tandem gait and bal-
ance can occur in some ET patients; this gait has been 
described as ataxic  [11, 12] . ET patients with intention 
tremor have other cerebellar signs such as disdiadocho-
kinesia  [13] . Mild oculomotor abnormalities have been 
documented in ET as well  [14] . The presence of a variety 
of nonmotor features, including specific personality traits 
 [15, 16] , anxiety  [17] , depressive symptoms  [4, 18–20] and 
social phobia  [21] ,   is gaining wider recognition  [22, 23] . 
Mild cognitive changes (especially executive dysfunc-
tion) have been documented in 6 studies  [24–29]   and in-
creased odds and risk of dementia in 2  [30, 31] . Hence, the 
view of ET that is emerging from clinical studies is that 
this heterogeneous condition is probably a family of dis-
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 Abstract 
 Background: Essential tremor (ET) is one of the most com-
mon neurological disorders. Despite this, the disease mech-
anisms and etiology are not well understood. While suscep-
tibility genotypes undoubtedly underlie many ET cases, no 
ET genes have been identified thus far. As with many other 
progressive, degenerative neurological disorders, it is likely 
that environmental factors contribute to the etiology of ET. 
Environmental epidemiology is the study in specific popula-
tions or communities of the effect on human health of phys-
ical, biologic and chemical factors in the external environ-
ment. The purpose of this article is to review current knowl-
edge with regards to the environmental epidemiology of ET. 
 Results: As will be discussed, a series of preliminary case-
control studies in recent years has begun to explore several 
candidate toxins/exposures, including harmane (1-methyl-
9H-pyrido[3,4-b]indole), lead and agricultural exposures/
pesticides.  Conclusions: While several initial results are 
promising, as will be discussed, additional studies are need-
ed to more definitively establish whether these exposures 
are associated with ET and if they are of etiological impor-
tance.  Copyright © 2008 S. Karger AG, Basel
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eases whose central defining feature is action tremor of 
the hands but in which there is considerable clinical het-
erogeneity  [1, 7, 32] .
 Epidemiology of ET 
 There have been more than 20 studies of the preva-
lence of ET  [33, 34] . Estimates of the crude prevalence of 
this disorder have varied considerably from study to 
study, with a number of methodological considerations 
(for example, use of screening questionnaires in order to 
select participants for tremor examinations) contributing 
greatly to this variability. However, in a population-based 
study in Turkey, in which all individuals were examined 
by a study neurologist, the prevalence of ET was 4.0% 
among individuals aged 40 years and older and 6.3% 
among individuals  6 60 years of age  [33] . In another pop-
ulation-based study in Finland that used a similar meth-
odology  [35] , the prevalence was 5.6% in individuals aged 
40 years and older and 9.0% among individuals  6 60 
years of age. Although an age-associated increase in prev-
alence is a consistent finding across studies  [34] , and 
prevalence is highest after the sixth decade  [33, 34] , the 
disorder can on occasion begin in childhood  [36, 37] , 
with many of these young-onset cases being familial  [3, 
38, 39] . While prevalence appears to be similar in men 
and women, it has been reported to be marginally higher 
in Caucasians than African-Americans  [40–42] .
 Two studies have provided estimates of the incidence 
of ET. In one study  [43] , which used a records linkage sys-
tem to capture all health encounters with individuals 
with ET, the age- and sex-adjusted incidence was 23.7 per 
100,000 White US population. Another study  [44] , which 
sampled ET cases directly from the population in the Ma-
drid region, reported an incidence (age  6 65 years) of 616 
per 100,000, which was substantially higher than that of 
the prior study. 
 Despite the fact that it is a progressive disorder  [45–
47] , there are few longitudinal data in patients with ET. 
In one study  [48] , 44 patients were followed prospective-
ly for 4 years and accelerometric data demonstrated an 
approximately 7% increase in arm tremor amplitude per 
year, while in another clinical study, an approximately 
12% annual change was reported in clinical tremor rat-
ings  [49] . These studies confirm the clinical anecdotal 
sense that the action tremor of ET worsens over time. 
 A wealth of clinical data centers on the apparent links 
between ET and Parkinson’s disease (PD)  [50–56] .   The 
development of PD has often been described in ET pa-
tients  [50, 56, 57] .   In recent studies, ET patients were 2–4 
times more likely to develop PD (that is, ET plus PD) 
when compared to persons without ET  [57, 58] . ET-like 
action tremor is more common in PD families than con-
trol families  [52] , further supporting the links between 
ET and PD, and postmortem studies have now shown 
that a subset of ET patients has brainstem (mainly in the 
locus ceruleus) Lewy bodies  [59–61] . 
 Mild cognitive changes (especially executive dysfunc-
tion) have been documented in 6 studies of ET, several of 
which had a case-control design  [24–29] .   One study fur-
ther showed an increased odds of prevalent dementia and 
then an increased risk of incident dementia in older-on-
set ET cases when compared with age-matched controls 
 [30, 31] . 
 Studies of mortality are conflicting. While the tradi-
tional belief had been that ET was not associated with 
mortality, there were few data and these data were retro-
spective  [43] . Recent data from a prospective, population-
based study in Spain, showed a 45% increased risk of 
mortality in ET, suggesting that the disease may be asso-
ciated both with increased morbidity and mortality 
 [62] .
 A number of factors may influence the clinical expres-
sion of ET. First, there seems to be an association between 
age of onset and rate of clinical progression, with older-
onset cases having a faster rate of progression  [46] . Fur-
thermore, the odds of developing head tremor are mark-
edly higher in women with ET than men with ET  [63–
65] .
 Underlying Disease Mechanisms 
 It is important to consider the underlying pathological 
anatomy and mechanistic basis of a disease when inves-
tigating how and where a putative etiological agent like a 
toxin enters the brain and then how it produces patho-
genic effects. The underlying anatomic pathology of ET 
has been elusive, although recent postmortem studies 
have begun to reveal some of the basic underlying degen-
erative brain changes in patients with this disease. These 
studies demonstrate 2 different pathologically defined 
subgroups of ET patients: the majority has degenerative 
changes [Purkinje cell loss and torpedoes (swellings of 
the Purkinje cell axon)] in the cerebellum (cerebellar ET), 
while a smaller number has brainstem Lewy bodies 
(mainly in the locus ceruleus) with a relatively preserved 
cerebellum (Lewy body variant of ET)  [59, 66, 67] . The 
presence of Lewy bodies in some ET cases is intriguing 
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and, as noted above, may explain the apparent clinical 
links between ET and PD. From an epidemiological per-
spective, this raises the possibility that the same set of 
environmental risk factors might trigger both diseases.
 Etiology of ET 
 ET is often considered to be largely a genetic disorder 
 [68–74] . There are numerous published examples of fam-
ilies in which the proband and multiple relatives have ET 
 [68, 70–72, 74–79] and in which the pattern of inheritance 
is most consistent with an autosomal dominant model. In 
1997, linkage was demonstrated to a region on chromo-
some 2p22-25 in several American families  [70] and, in 
that same year, to chromosome 3q13 in 16 Icelandic fam-
ilies  [74] . Since then, one other study has demonstrated 
linkage to a region on chromosome 6p23 in several North 
American families  [73] . Other studies have failed to dem-
onstrate linkage to these 3 regions, indicating further ge-
netic heterogeneity  [69, 72, 80, 81] . Studies have not pro-
gressed further and no ET genes have been identified so 
far  [69, 70, 73, 74] . A number of studies have also explored 
the role of genetic polymorphisms in ET  [77, 82–90] , with 
single reports of associations between ET and polymor-
phisms in the following genes: glutathione-S-transferase 
P1 (involved in metabolism of carcinogens)  [84] ,  ! -ami-
no-levulinic acid dehydrogenase (involved in lead kinet-
ics)  [86] , methylenetetrahydrofolate reductase (involved 
in folate- and vitamin B 12 -dependent homocysteine me-
tabolism)  [83] and CYP2C19 (possibly related to primi-
done metabolism)  [85] .
 Although widely considered to have a large genetic 
component, it is likely that environmental factors con-
tribute to the etiology of ET as well. First, it is commonly 
stated in the literature that 50% or more of ET cases have 
a genetic basis, although some estimates are as low as 17% 
 [91] . In the only familial aggregation study of ET  [92] , 
55% of ET cases had no affected first- or second-degree 
relatives, despite examination of 4.5 relatives per case, on 
average. This was consistent with data from other series, 
among whom the majority ( 1 50%) of ET cases do not re-
port affected relatives  [20, 91, 93–97] . Second, in twin 
studies  [98, 99] concordance in monozygotic twins was 
 ! 100% (that is, it was 60% in one study and 63% in an-
other). Third, the existence of intrafamilial differences in 
age of onset and severity of tremor  [100, 101] also suggests 
that environmental (or perhaps other genetic) factors 
may be serving as modifiers of an underlying susceptibil-
ity genotype. Fourth, temporal trends in disease inci-
dence can support the notion that environmental factors 
may be contributing to the etiology of ET. A temporal 
trend in the annual incidence of ET was reported in Roch-
ester, Minnesota  [43] , where the annual age-adjusted in-
cidence per 100,000 rose from 5.8 in the period from 1935 
to 1949, to 15.8 in the period from 1950 to 1964 and 23.5 
from 1965 to 1975. These data, however, should be ap-
proached with caution as this trend could also be the re-
sult of increased recognition and diagnosis of the disor-
der rather than a true rise in disease incidence. 
 Environmental factors are also thought to play a sub-
stantial role in other neurological disorders (PD, Alz-
heimer’s disease, amyotrophic lateral sclerosis)  [102–113] , 
so that it is not inconceivable that they could play a role 
in ET. Using the commonly cited value of 50% for the 
percentage of cases that occur on a familial basis  [91, 114] , 
and given its population prevalence of 4.0% after age 39 
years  [33] , this then suggests that approximately 2.0% of 
the population aged  6 40 years has a nonfamilial form of 
ET  [33] . Despite the apparent extent of the problem, the 
environmental correlates for this tremor are just begin-
ning to be explored. 
 Possible Environmental Toxins in ET 
 Harmane (1-methyl-9H-pyrido[3,4-b]indole) 
 In the selection of possible toxic causes of ET for in-
vestigation, the  " -carboline alkaloids are a reasonable 
choice. They are a group of naturally occurring chemicals 
that include harmane, norharman, harmine, harmaline 
and others  [115–117] .  " -Carboline alkaloids are a type of 
heterocyclic amine; structurally, they are comprised of a 
combination of 5- and 6-ringed (that is, cyclic) carbon 
structures, which contain an amine group  [118] . There is 
a structural similarity with the neurotoxin 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), which forms 
the basis for one of the main toxin-induced animal mod-
els for PD  [119, 120] . Like MPTP,  " -carboline alkaloids 
are highly neurotoxic, and it has been known for approx-
imately 100 years that administration of  " -carboline al-
kaloids to a wide variety of laboratory animals produces 
an intense and generalized action tremor resembling ET 
 [121] .  " -Carboline alkaloid administration is currently 
the main animal model for ET and it has been proposed 
that new pharmacotherapies be tested using exposed an-
imals  [122–126] . The  " -carboline alkaloid tremor shares 
many features with ET, including its principal clinical 
features (such as tremor frequency), drug response char-




barbiturates)  [126–131] and underlying brain changes 
(changes in the cerebellum, including Purkinje cell loss, 
have now been documented in ET  [67, 132–137] ; simi-
larly,  " -carboline alkaloids produce toxic damage with 
significant loss of cerebellar Purkinje cells)  [121, 126, 127, 
138–141] . Among human volunteers exposed to intrave-
nously administered harmine, neurological effects in-
clude an acute, coarse tremor  [142, 143] .
 Harmane (1-methyl-9H-pyrido[3,4-b]indole) is among 
the more potent tremor-producing  " -carboline alkaloids 
 [115] . Harmane itself is also very lipid soluble  [116] and 
broadly distributed within the rat brain  [144–146] . Brain 
concentrations are several fold higher than those in the 
blood  [116, 145] . 
 While  " -carboline alkaloids are produced endoge-
nously  [147, 148] , one study estimated that dietary sourc-
es were 50 times greater than these endogenous sources 
 [149] .  " -Carboline alkaloids are found in particularly 
high nanogram/gram concentrations in muscle foods 
(beef, chicken and pork) and cooking leads to further-
more increased concentrations  [150–153] . Indeed, the 
formation of  " -carboline alkaloids in cooked meat is a 
function of cooking temperature and time, with  " -car-
boline alkaloid concentrations increasing most rapidly 
with time at higher temperatures  [154, 155] . Pan frying 
and grill/barbequing produce the highest concentrations 
of  " -carboline alkaloids. In addition to their high con-
centration in meat,  " -carboline alkaloids are also present 
in varying concentrations in plant-derived foods/sub-
stances, including coffee, ethanol and tobacco  [156] .
 In 2002, Louis et al.  [157] demonstrated that blood 
harmane concentration was elevated in 100 ET patients 
at the Neurological Institute of New York compared to 
100 matched control subjects (median blood harmane: 
5.21 g –10 /ml  in cases vs. 2.28 g –10 /ml in controls, p = 
0.005). In analyses that adjusted for age and other con-
founders, there was a robust association between log 
blood harmane concentration and ET diagnosis: odds ra-
tio (OR) ET vs. control = 1.80, 95% confidence interval (CI) = 
1.10–2.93, p = 0.02 (that is, each 1 g –10 /ml increase in 
blood harmane concentration was associated with an 
80% increased odds of ET)  [157] . With continued enroll-
ment from the years 2002–2007, a larger replicate sample 
of 150 ET cases and 135 matched controls was assembled 
 [158] . While overall concentrations were lower in this 
sample, the case-control difference persisted (median 
blood harmane: 2.61 g –10 /ml in cases vs. 1.82 g –10 /ml in 
controls, p = 0.016)  [158] .
 Using magnetic resonance spectroscopic imaging, 
Louis et al.  [159] also demonstrated a strong inverse cor-
relation between cerebellar  N -acetyl aspartate to creatine 
ratio (a marker of neuronal damage) and blood harmane 
concentrations (p = 0.009, adjusting for age and gender) 
in a small study of 12 ET cases. This correlation was not 
found in other brain regions (such as thalamus and basal 
ganglia) or with other neurotoxins (such as lead)  [159] . 
These findings suggest that increased blood harmane 
concentration could be associated with greater cerebellar 
neuronal damage, consistent with the animal study data 
that harmane and other  " -carboline alkaloids produce 
cerebellar damage  [121, 126, 127, 138–141] . Studies of hu-
man postmortem tissue are needed to further test this 
association.
 As noted above, harmane is found in high concentra-
tions in cooked meats. In an initial study in 2005, Louis 
et al.  [160] compared animal protein consumption in 106 
ET cases versus 161 controls. Total daily animal protein 
consumption was similar in cases and controls (50.2  8 
19.6 vs. 49.4  8 19.1 g/day, p = 0.74). However, the study 
used a standardized food frequency questionnaire  [161] . 
In a follow-up study  [162] , a more detailed meat con-
sumption questionnaire was used. In that study, total 
meat consumption was greater in men with ET versus 
men without ET (135.3  8 71.1 vs. 110.6  8 80.4 g/day, 
p = 0.03) but not in women with versus without ET (80.6 
 8 50.0 vs. 79.3  8 51.0 g/day, p = 0.76). Male ET cases had 
a higher odds of being in the highest versus lowest quar-
tile of current meat consumption than did male controls 
(unadjusted OR = 9.29, 95% CI = 2.29–37.64, p = 0.002; 
adjusted OR = 21.36, 95% CI = 3.52–129.51, p = 0.001). 
That study provided preliminary evidence of a dietary 
difference between males with ET versus males without 
ET  [162] , raising the question whether this possible di-
etary difference, through harmane consumption, could 
be linked with ET.
 The study of harmane and its association with ET has 
been intriguing, yet the links need to be further devel-
oped and convincingly established. There are a number 
of basic unanswered questions. First, although elevated 
harmane concentrations have been observed in ET cases 
in blood, it is not known whether brain concentrations of 
this neurotoxin are elevated in ET. Second, current data 
were derived from a single study of ET cases mainly from 
a tertiary referral center and they need to be reproduced 
elsewhere. Third, one small study found elevated blood 
harmane concentrations in patients with PD  [163] , which 
raises the question as to whether elevated blood harmane 
is specifically linked with ET or if it is merely a more gen-
eral, global marker of neurological illness. Addressing 
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association between ET and this neurotoxin. Additional 
studies would also be required to demonstrate that the 
exposure preceded the disease and was of etiological im-
portance.
 Lead 
 Human beings may be exposed to organic and inor-
ganic forms of lead through a number of occupational 
and nonoccupational sources  [164, 165] . In both labora-
tory animals and human beings, lead exposure may result 
in an acute or chronic progressive disorder in which ac-
tion tremor is a prominent feature  [164, 166–170] . Lead 
exposure produces a destructive cerebellar pathology. 
Thus, rat pups fed a diet containing 4% lead acetate dem-
onstrated changes in Purkinje cell morphology  [171] . 
Perinatal exposure to inorganic lead results in degenera-
tive changes in rabbit Purkinje cells  [172] . Postmortem 
examination of humans with chronic organic lead expo-
sure revealed marked destruction of Purkinje cells  [169] . 
This is of particular interest given the observation, noted 
above, of cerebellar pathology in ET  [67, 132–137] .
 Preliminary evidence suggests that there may be an 
association between lead exposure and ET. In an initial 
study at a tertiary referral center in New York  [173] , blood 
lead concentrations were measured and a lifetime occu-
pational history was assessed in 100 ET patients and 143 
matched controls. Although blood lead concentrations 
were low in absolute terms, these concentrations were 
higher in ET patients than in controls (median: 2.7 vs. 2.3 
mg/dl; p = 0.038). In an adjusted logistic regression mod-
el, blood lead concentration was associated with ET diag-
nosis: OR = 1.19; 95% CI = 1.03–1.37, p = 0.02 (that is, each 
1 mg/dl increase in blood lead concentration was associ-
ated with a 19% increased odds of ET). Whether the ob-
served association was due to increased exposure to lead 
or a difference in lead kinetics/metabolism was not inves-
tigated. The prevalence of a history of lifetime occupa-
tional lead exposure was similar in ET patients and con-
trols. In a second study  [86] , the mechanism was explored 
further. The  ! -amino-levulinic acid dehydratase (ALAD) 
gene codes for ALAD, the principal enzyme involved in 
lead kinetics. Carriers of the ALAD-2 allele may be more 
susceptible to lead toxicity. Eighteen (28.6%) of sixty-
three ET cases versus 17 (16.8%) of 101 controls had an 
ALAD-2 allele (OR = 1.98, 95% CI = 0.9–4.2, p = 0.077) 
and there was an interaction between blood lead concen-
tration and ALAD allele status; the odds of ET were 
greatly elevated (OR = 80.3; 95% CI = 3.1–2,096.4, p = 
0.008) in individuals with both an ALAD-2 allele and an 
elevated blood lead concentration. Blood lead concentra-
tion was later evaluated in a second study of ET patients 
at a hospital in Turkey  [174] . In that study, the median 
blood lead concentration was 2.7 mg/dl in 105 ET cases 
versus 1.5 mg/dl in 105 controls (p  ! 0.001). In a logistic 
regression model, blood lead concentration was associ-
ated with ET diagnosis: OR = 4.0; 95% CI = 2.5–6.4, p  ! 
0.001 (that is, each 1 mg/dl increase in blood lead concen-
tration was associated with a 4-fold increased odds of 
ET). These data replicated those of the previous study in 
New York.
 The possible association of lead exposure with ET is 
intriguing, yet it needs to be further explored with addi-
tional replicate samples, preferably from population-
based studies. Furthermore, bone lead concentration, 
which is a more valid measure of chronic lead exposure 
than blood lead, needs to be assessed in ET cases and con-
trols. 
 Pesticides 
 There is a sizable literature on the association between 
pesticide exposure and PD  [104, 107, 108] . As a class of 
chemicals, pesticides can produce tremor (including ac-
tion tremor), and organochlorine pesticides (OCPs) are 
particularly tremorogenic in animals and humans  [175–
178] . The literature on pesticide exposure and ET, how-
ever, is limited to few studies  [177] . In a study in New York 
 [177] , 6 serum OCP concentrations and lifetime occupa-
tional histories were assessed in 136 ET cases ascertained 
from a tertiary referral center and 144 matched control 
subjects. The 6 serum OCP concentrations were similar 
in cases and controls. Three (2.2%) ET cases versus 9 
(6.3%) controls had past occupational exposure to OCPs. 
This apparent lack of a case-control difference in self-re-
ported exposure to pesticides was confirmed in a second 
study in Spain of 142 ET patients and 284 controls  [179] 
as well as a third study in Singapore of 79 ET patients and 
100 controls, which demonstrated no difference in terms 
of self-reported pesticide exposure  [180] . Exposure histo-
ries in each study, however, were brief. These studies rep-
resent a beginning and additional studies of ET are need-
ed to assess a wider array of pesticides in more detail, 
using occupational histories, assessments of residential 
exposures and biological measures. 
 Other Exposures 
 A small number of studies have examined other po-
tential exposures and their relation to ET. One study at a 
tertiary referral center in New York examined whether 
occupational exposures to manganese or organic solvents 




 [181] .  This lack of association was confirmed in a second 
study in Spain of 142 ET patients and 284 controls  [179] . 
In a study in Italy of 27 dental technicians (mean age 49.1 
years, no controls), 4 (14.8%) had mild postural tremor 
 [182] , raising the issue of occupational toxin exposure, 
but these results are difficult to interpret given the high 
prevalence of postural tremor in the population  [183] . 
While the issue of pesticide exposure was discussed 
above, 2 studies have raised questions about the more 
general association between agricultural exposures and 
ET. A small door-to-door survey in Italy that included 28 
ET cases and 28 controls noted that the odds for habitual 
exposure to agricultural chemicals and domestic animals 
were 2.5 and 2.7 times higher in ET cases, respectively 
(results not significant)  [95] ;  each of these factors has 
been reported to be associated with PD  [184] . A study of 
142 clinic patients and 282 controls in Spain similarly re-
ported that exposure to agricultural work was associated 
with ET (for agricultural exposure, OR = 25.4, 95% CI = 
1.43–4.51, p = 0.002); however, reported family history 
was more strongly associated with ET in that study 
(OR = 34.2, 95% CI = 18.1–64.7, p  ! 0.001)  [179] . Addi-
tional studies are needed.
 Ethanol 
 Patients with ET may use ethanol to temporarily less-
en the amplitude of their tremor  [185, 186] , although 
quantitative studies on relative ethanol consumption in 
ET cases versus controls have yielded mixed results  [187] . 
The generally accepted causal pathway is that having ET 
might lead to increased ethanol consumption rather than 
the converse. Given this model, ethanol would not be 
considered a risk factor for ET. However, ethanol is a 
known cerebellar toxin, resulting in profound Purkinje 
cell loss  [188] . Given the emerging links between ET and 
cerebellar pathology  [66] , this raises the question as to 
whether ethanol consumption might be associated with 
increased risk of incident ET, earlier age of onset of inci-
dent ET or more rapid rate of progression of prevalent ET. 
These issues have not been studied.
 Possible Protective Exposures (Cigarettes) 
 Numerous studies have demonstrated an association 
between cigarette smoking and lower risk of PD  [189, 
190] . Three studies, all in Spain, have examined smoking 
habits in ET cases compared to controls  [179, 191, 192] . In 
the first of these  [179] , the proportion of ET clinic patients 
and controls who smoked was similar, yet the number of 
cigarette pack years was marginally lower in cases than 
in controls. The second of these studies was a population-
based study in Madrid  [191] . In that study, ever smokers 
were approximately one half as likely to have prevalent 
ET when compared with never smokers (OR = 0.58, 95% 
CI = 0.40–0.84, p = 0.004) and ever smokers in the high-
est cigarette pack year tertile were one third as likely to 
have ET when compared with never smokers (adjusted 
OR = 0.39, 95% CI = 0.22–0.69, p = 0.001). Finally, in the 
same study, the association between baseline smoking 
and incident ET was later examined  [192] . Five (6.5%) of 
seventy-seven incident ET cases had been smokers at 
baseline compared with 392 (12.0%) of 3,271 controls 
(p = 0.14). Baseline pack years were lower in incident ET 
cases than controls (9.2  8 17.7 vs. 15.7  8 28.4, p = 0.002). 
In Cox proportional hazards models, highest baseline 
pack year tertile was associated with lower risk of inci-
dent ET; those in the highest baseline pack year tertile 
were one third as likely to develop incident ET when com-
pared to nonsmokers (adjusted relative risk = 0.29, 95% 
CI = 0.09–0.90, p = 0.03).
 The biological basis for an association between ciga-
rette smoking and possible lower risk of incident ET is not 
clear. Nicotine has been the focus of this effect for sev-
eral reasons. First, nicotine is known to protect against 
the degenerative effects of toxic insults in different ex-
perimental systems  [193–195] . Nicotine pretreatment 
consistently reduces the detrimental effects of excitotox-
in exposure in cultured cells  [193–195] , including neuro-
toxin-induced degeneration of nigral dopamine-contain-
ing neurons  [196] . Finally, in rats and mice, nicotine can 
protect against Parkinsonism-inducing neurotoxins like 
MPTP and methamphetamine  [197] . 
 While early epidemiological studies appear to show an 
inverse dose-dependent association between smoking 
and the risk of ET, additional prospective studies are 
needed to further explore the possible protective effects 
of smoking on risk of ET. Even if such studies were to be 
confirmatory, given the other adverse health effects of 
smoking, this activity should not be considered a prudent 
strategy for reducing the risk of ET. 
 Caveats 
 ET is a common and very widespread disorder whose 
etiology is likely to be the result of a complex variety of 
factors. A particular neurotoxin is likely to play an etio-
logical role only in subsets of ET cases, which makes it 
more difficult to explore and establish such associations 
when one has no understanding of and has not yet identi-
fied those subsets.
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 Furthermore, while one scenario is that a neurotoxin/
environmental factor is by itself sufficient to result in a 
neurological disease, another possibility is that the toxin 
merely increases the propensity for developing the disor-
der. For example, a toxin might result in a set of biological 
changes in the cerebellum (such as Purkinje cell loss), 
which then increase the exposed individual’s sensitivity 
to the toxic effects of a second event.
 Summary 
 While ET is widely considered to have a large genetic 
component  [68–74] , it is likely that environmental factors 
contribute to the etiology of ET as well. Such factors are 
similarly thought to play a substantial role in other pro-
gressive, degenerative neurological disorders  [102–113] . 
Work over recent years has explored a number of expo-
sures, including harmane, lead and agricultural expo-
sures/pesticides in preliminary case-control studies, but 
further work is needed to more fully establish whether 
these toxins are risk factors for ET. Initial work also sug-
gests that cigarette smoking might be protective of ET.
 By some estimates, 2.0% of the population aged  6 40 
years has a nonfamilial form of ET. Despite these high 
numbers, the environmental correlates for this tremor 
are just beginning to be explored.
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